The alteration of plasma lipoproteins by cremophor EL.
نویسندگان
چکیده
Cremophor EL (CRM) is a non-ionic amphipathic emulsifier which has been used as a parenteral vehicle for many hydrophobic drugs. At concentrations above 0.4 mg ml-1, CRM alters lipoproteins so as to reduce their electrophoretic mobility; high density lipoprotein (HDL) is somewhat more sensitive than low density lipoprotein (LDL) in this regard. The same phenomenon was observed with Triton X-100 and Tween-80, two other non-ionic detergents. Ultracentrifugation experiments show that CRM alters the density of HDL resulting in a product with approximately the same specific gravity as LDL. Administration of mesoporphyrin solubilized with CRM to the mouse resulted in a rapid clearance of porphyrin bound to this new HDL species. Such a phenomenon may account for reports which indicate that CRM promotes the distribution of photosensitizing agents to neoplastic tissues.
منابع مشابه
Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.
The aim of the present study was to determine whether Cremophor EL is a suitable surfactant that can be routinely applied to pharmacokinetic (PK) studies in early drug discovery without influencing the intrinsic PK characteristics of the new chemical entities (NCEs). Cremophor EL, a polyoxyl 35 castor oil, has been used as a solubilization aid for water-insoluble compounds in pre-clinical drug ...
متن کاملCremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
We have determined the in vitro and in vivo cellular distribution of the antineoplastic agent paclitaxel (Taxol) in human blood and the influence of Cremophor EL (CrEL), the vehicle used for i.v. drug administration. In the absence of CrEL, the blood:plasma concentration ratio was 1.07+/-0.004 (mean+/-SD). The addition of CrEL at concentrations corresponding to peak plasma levels achieved after...
متن کاملPhase I trial of cremophor EL with bolus doxorubicin.
Cremophor EL (cremophor), a component of the paclitaxel formulation, can potentially reverse P-glycoprotein-associated multidrug resistance. A Phase I trial of cremophor as a 6-h infusion every 3 weeks was performed with bolus doxorubicin (50 mg/m2). The cremophor dose was escalated from 1 to 60 ml/m2. A standard paclitaxel premedication was given before cremophor. Using a bioassay, potentially...
متن کاملThe Effect of Temperature, pH, and Different Solubilizing Agents on Stability of Taxol
Inabilities to attain adequate aqueous solubility and stability have made the preparation of a clinically suitable formulation of taxol difficult. Addition of nicotinamide (ND), 2-hydroxypropyl- b-cyclodextrin (HPßCD), polyethylene glycol, (PEG), bile salts (BS, 50:50 sodium cholate: deoxycholate...
متن کاملPaclitaxel, a diterpenoid derived from the needles and bark
of the Pacific yew tree, is a potent inhibitor of cell replication, blocking cells in the late G2-mitotic phase of the cell cycle by stabilizing the microtuble cytoskeleton. Clinical trials have shown that paclitaxel has antineoplastic activity, particularly against primary epithelial ovarian carcinoma, breast cancer, colon, head and neck cancers and non-small cell lung cancer. Paclitaxel is a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of photochemistry and photobiology. B, Biology
دوره 22 3 شماره
صفحات -
تاریخ انتشار 1994